Mr. Andre Larente reports

DIAGNOS WILL START A CLINICAL TRIAL STUDY IN THE USA COMMENCING DECEMBER 6TH, 2021 FOR EARLY DETECTION AND PREVENTION OF STROKE USING CARA-STROKE.

Diagnos Inc. will begin a clinical trial study with CommonSpirit Health Research Institute and Chattanooga Center for Neurologic Research LLC, and conducted at the CommonSpirit Hospital in Chattanooga, to confirm early proof-of-concept results that showed a strong potential in the early detection of stroke through the inspection and analysis of the retina.

The clinical trial will be carried out under the direction of Thomas G. Devlin, MD, PhD. The institutional review board (IRB) study has been approved by an institutional review board in compliance with all applicable regulations in the United States. Diagnos will be starting the clinical trial the week of Dec. 6 -- Diagnos will be seeking to demonstrate that CARA-ST (CARA ((computer-assisted retina analysis)) stroke) will be able to predict the early signs of the condition leading to a stroke, based on the micro circulation analysis of the retina image of the patient.

As per the Center for Disease Control and Prevention (CDC), stroke causes one out of every 20 deaths; the management of stroke represents a cost of around $34-billion (U.S.) per year in the United States. Hence, early diagnosis and treatment to prevent deaths from stroke is a time sensitive necessity.

According to the World Health Organization, 15 million people suffer a stroke worldwide each year. Of these, five million die and another five million are permanently disabled. High blood pressure contributes to more than 85 per cent of strokes worldwide. Europe averages approximately 650,000 stroke-related deaths each year.

"According to new reports published by worldwide research institutes, the worldwide market size for stroke management will hit over $66-billion by 2023. Diagnos intends to be part of the solution by making available an affordable predictive test to the general public," said Andre Larente, president of Diagnos.

"This year, our new stroke management application will be field tested in multiple countries. For our investors, this groundbreaking test comes at an ideal time in terms of shareholder value creation as the combination of both CARA-DR and CARA-ST tools will be transformational in helping to monitor the health of existing and future patients with cardiovascular disease," said Mr. Larente, president of Diagnos.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA. CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.